PhoenixBio Co.,Ltd.【JP:6190】
Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
| Period End | EBITDA (Million JPY) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -114 | -413.83% |
| Mar 31, 2024 | 36 | -93.18% |
| Mar 31, 2023 | 532 | -753.90% |
| Mar 31, 2022 | -81 | -63.25% |
| Mar 31, 2021 | -221 | +137.23% |
| Mar 31, 2020 | -93 | -66.88% |
| Mar 31, 2019 | -282 | +15.42% |
| Mar 31, 2018 | -244 | -246.07% |
| Mar 31, 2017 | 167 | -21.33% |
| Mar 31, 2016 | 212 | +194.35% |
| Mar 31, 2015 | 72 |